- In patients with relapsed/refractory (R/R) B-cell malignancies, sequential CD19- and CD22-directed chimeric antigen receptor-engineered T cells (CAR19/22) was safe and effective, and associated with a low rate of antigen escape relapse.
Why this matters
- Malignant B cells have developed multiple antigen escape mechanisms driving CD19-negative relapse following CD19-directed therapy.
- Study to investigate infusion of 2 sequential CAR-T cell therapies in 89 patients with R/R B-cell malignancies.
- Funding: National Natural Science Foundation of China; Natural Science Foundation of Hubei Province; Huanghe Talents Plan of Wuhan City; National High Technology Research and Development Program of China; Milstein Medical Asian American Partnership Foundation; Applied Basic Research Project of Wuhan City.
- In acute lymphoblastic leukemia (n=51):
- 96.0% (95% CI, 86.3%-99.5%) achieved minimal residual disease negativity (MRD−).
- At 16.7 (range, 1.3-33.3) months median follow-up:
- 31.0 months (95% CI, 10.6 to NR) median OS.
- In non-Hodgkin lymphoma (n=38):
- 72.2% (95% CI, 54.8%-85.8%) overall response; 50.0% (95% CI, 32.9%-67.1%) complete response.
- At 14.4 (range, 0.4-27.4) months median follow-up:
- 18.0 months (95% CI, 6.1 to NR) median OS.
- 1 patient experienced antigen loss relapse.
- Limited sample size.